• Citer

PSMA-targeted PET imaging in patients with metastatic triple-negative breast cancer: results of the prospective PRISMA trial.

par Manley, Martin;Nader-Marta, Guilherme;Ozturk, Ayça Arcay;Kassas, Mutaz ;Rothé, Francoise;Taraji, Loubna;Sotiriou, Christos ;Wimana, Zéna;Salgado, Roberto;Flamen, Patrick;Gebhart, Géraldine
Référence European journal of nuclear medicine and molecular imaging
Publication Publié, 2025-11

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Résumé :

Radioligand therapy (RLT) targeting prostate-specific membrane antigen (PSMA) improves survival in metastatic castration-resistant prostate cancer. PSMA is also expressed in triple-negative breast cancer (TNBC), a subtype with limited treatment options. This prospective study assessed PSMA uptake on [68Ga]Ga-PSMA-11 PET/CT in patients with metastatic TNBC (mTNBC) to evaluate the feasibility of PSMA-targeted RLT.